secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0001104659-25-052729
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma gets FDA guidance on bird flu drug tivoxavir; details stockpiling plans; cash $15.9M
--------------------------------------------------------------------------------

- Received FDA guidance on path forward for tivoxavir marboxil (TXM) for bird flu and seasonal flu; pursuing Animal Rule for accelerated approval.
- Preclinical data: single oral dose of TXM protected against lethal H5N1 (dairy-worker strain) in mice, ferrets, and non-human primates.
- Phase 1 data: single 480 mg dose maintained plasma levels above EC90 for ~3 weeks; no treatment-related adverse events.
- US strategic stockpile estimated at 300-600 million doses; company discussing TXM inclusion with BARDA.
- Cash and equivalents of $15.9M as of March 31, 2025; expected runway into Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925052729/0001104659-25-052729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925052729/tm2516160d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-052729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer